18,276 Novartis AG $NVS Shares Sold by Keybank National Association OH

Keybank National Association OH trimmed its position in shares of Novartis AG (NYSE:NVS) by 25.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,448 shares of the company’s stock after selling 18,276 shares during the period. Keybank National Association OH’s holdings in Novartis were worth $7,620,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. SOA Wealth Advisors LLC. lifted its holdings in shares of Novartis by 4,316.2% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 14,750 shares of the company’s stock valued at $2,312,000 after buying an additional 14,416 shares during the last quarter. Mission Wealth Management LP increased its holdings in Novartis by 85.7% in the second quarter. Mission Wealth Management LP now owns 19,690 shares of the company’s stock worth $3,086,000 after buying an additional 9,086 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Novartis by 40.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 195,986 shares of the company’s stock worth $30,715,000 after buying an additional 56,424 shares during the last quarter. QRG Capital Management Inc. increased its holdings in Novartis by 9.0% in the second quarter. QRG Capital Management Inc. now owns 164,478 shares of the company’s stock worth $25,777,000 after buying an additional 13,634 shares during the last quarter. Finally, Somerville Kurt F bought a new position in Novartis during the second quarter valued at approximately $1,636,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Top Novartis Stories

Here are a few of the latest stories about NVS:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $9.06 from $8.83 and its FY2027 estimate to $9.91 from $9.75. It also increased several quarterly forecasts, including Q3 2027 to $2.57 from $2.45. The revisions suggest improved expectations for some periods, though the FY2026 estimate is close to the cited $9.08 consensus. Zacks Research estimate revisions
• Positive Sentiment: A Zacks article characterized Novartis as a potential momentum-investor pick, which may support positive sentiment, although the provided summary does not specify the underlying momentum metrics. Zacks momentum article
• Negative Sentiment: Zacks Research trimmed its FY2028 EPS forecast to $10.62 from $10.69 and lowered estimates for some quarters, including Q1 2028 to $2.45 from $2.54. These cuts temper the positive revisions, though they are modest and concern future periods. Zacks Research estimate revisions

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on NVS shares. DZ Bank began coverage on shares of Novartis in a research note on Wednesday, October 28th. They issued a “hold” rating for the company. Jefferies Financial Group reissued a “neutral” rating on shares of Novartis in a report on Thursday, July 23rd. UBS Group reissued a “neutral” rating on shares of Novartis in a research report on Wednesday, October 28th. Berenberg Bank reduced their price objective on Novartis from $147.00 to $130.00 and set a “hold” rating for the company in a research report on Friday, September 11th. Finally, HSBC upgraded Novartis from a “reduce” rating to a “hold” rating and boosted their price target for the company from $123.00 to $136.00 in a research note on Thursday, September 10th. Six research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $152.25.

Novartis Stock Down 0.1%

NYSE NVS opened at $160.16 on Friday. Novartis AG has a 1-year low of $123.24 and a 1-year high of $170.46. The company has a market capitalization of $305.61 billion, a price-to-earnings ratio of 30.56, a PEG ratio of 2.93 and a beta of 0.40. The stock’s 50 day moving average is $149.18 and its two-hundred day moving average is $152.56. The company has a current ratio of 0.88, a quick ratio of 0.70 and a debt-to-equity ratio of 0.98.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.25 by $0.21. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.53 billion. Novartis had a return on equity of 41.04% and a net margin of 18.11%. Novartis’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.25 EPS. Equities analysts forecast that Novartis AG will post 9.10 earnings per share for the current fiscal year.

About Novartis

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.